A continuing black hole? The FDA boxed warning: An appeal to improve its clinical utility

References

• Associated Press 2009. FDA's drug approvals flat in 2009, safety up, http://www.msnbc.msn.com/id/34708085/ns/health-more_health_news/. Accessed 23 February 2011.
   Google Scholar
• Food and Drug Administration (FDA) 1979. 21 Code of Federal Regulations xx201.56, 201.57.
   Google Scholar
• Food and Drug Administration (FDA) 1979. 21 Code of Federal Regulations x201.57(e).
   Google Scholar
• Guidance for Industry Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products – Content and Format DRAFT GUIDANCE, January 2006. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075096.pdf. Accessed 23 February 2011.
   Google Scholar
• Liang BA. FDA use of the black box warning: time for reevaluation as a safety tool. J Clin Anesth 2002; 14:561–563.
   PubMed Web of Science ®Google Scholar
• Wood AJ. Thrombotic thrombocytopenic purpura and clopidogrel – a need for new approaches to drug safety. N Engl J Med 2000; 342: 1824–1826.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA) 2009. Dr. Curtis Rosebraugh (Director of Drug Evaluation II in the Center for Drug Evaluation and Research at FDA) from the Transcript for FDA's Media Briefing on the Serious Mental Health Risks Associated with the Drugs Chantix and Zyban, 1 July 2009. www.fda.gov/downloads/NewsEvents/Newsroom/Media/transcripts. Accessed 23 February 2011.
   Google Scholar
• Cook DM, Gurugubelli RK, Bero LA. Risk management policy and black-box warnings: a qualitative analysis of US FDA proceedings. Drug Saf 2009; 32:1057–1066.
   PubMed Web of Science ®Google Scholar
• Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002; 287:2215–2220.
   PubMed Web of Science ®Google Scholar
• Lurie P, Sasich LD. Safety of FDA-approved drugs. JAMA 1999; 282:2297–2298.
   PubMed Web of Science ®Google Scholar
• 2006 Safety Alerts for Human Medical Products, FDA, U.S. Department of Health and Human Services. www.fda.gov/safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/. Accessed 23 February 2011.
   Google Scholar
• Droperidol [package insert]. Taylor Pharmaceuticals. Decatur, IL. 2006.
   Google Scholar
• Gan TJ. “Black box’ warning on droperidol: report of the FDA convened expert panel. Anesth Analg 2004; 98:1809.
   PubMed Web of Science ®Google Scholar
• Fortney JT, Gan TJ, Graczyk S, Wetchler B, Melson T, Khalil S, . A comparison of the efficacy, safety, and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. S3A-409 and S3A-410 Study Groups. Anesth Analg 1998; 86:731–738.
   PubMed Web of Science ®Google Scholar
• Henzi I, Sonderegger J, Tramer MR. Efficacy, dose-response, and adverse effects of droperidol for prevention of postoperative nausea and vomiting. Can J Anaesth 2000; 47:537–551.
   PubMed Web of Science ®Google Scholar
• Bailey P, Norton R, Karan S. The FDA droperidol warning: is it justified? Anesthesiology 2002; 97:288–289.
   PubMed Web of Science ®Google Scholar
• Gan TJ, White PF, Scuderi PE, Watcha MF, Kovac A. FDA “black box” warning regarding use of droperidol for postoperative nausea and vomiting: is it justified? Anesthesiology 2002; 97:287.
   PubMed Web of Science ®Google Scholar
• Habib AS, Gan TJ. Food and drug administration black box warning on the perioperative use of droperidol: a review of the cases. Anesth Analg 2003; 96:1377–1379.
   PubMed Web of Science ®Google Scholar
• Jackson CW, Sheehan AH, Reddan JG. Evidence-based review of the black-box warning for droperidol. Am J Health Syst Pharm 2007; 64:1174–1186.
   PubMed Web of Science ®Google Scholar
• Kao LW, Kirk MA, Evers SJ, Rosenfeld SH. Droperidol, QT prolongation, and sudden death: what is the evidence? Ann Emerg Med 2003; 41:546–558.
   PubMed Web of Science ®Google Scholar
• Lischke V, Behne M, Doelken P, Schledt U, Probst S, Vettermann J. Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg 1994; 79:983–986.
   PubMed Web of Science ®Google Scholar
• Smith SW, Martel M, Biros M. QT lengthening after parenteral droperidol administration. Acad Emerg Med 2002; 9:374–375.
   Google Scholar
• Mieckowski A, Burns M. Droperidol and the Blackbox. Clin Toxicol (Phila) 2005; 40:669–670 (abstract).
   Google Scholar
• Habib AS, Gan TJ. The use of droperidol before and after the Food and Drug Administration black box warning: a survey of the members of the Society of Ambulatory Anesthesia. J Clin Anesth 2008; 20:35–39.
   PubMed Web of Science ®Google Scholar
• Nuttall GA, Eckerman KM, Jacob KA, Pawlaski EM, Wigersma SK, Marienau ME, . Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and torsade de pointes in the general surgical population? Anesthesiology 2007; 107:531–536.
   PubMed Web of Science ®Google Scholar
• Methadone-associated Deaths and Efforts to Prevent Them. Government Accountability Office Report to Congressional Requesters: GAO-09-341; March, 2009.
   Google Scholar
• Paulozzi LJ, Logan JE, Hall AJ, McKinstry E, Kaplan JA, Crosby AE. A comparison of drug overdose deaths involving methadone and other opioid analgesics in West Virginia. Addiction 2009; 104: 1541–1548.
   PubMed Web of Science ®Google Scholar
• Sims SA, Snow LA, Porucznik CA. Surveillance of methadone-related adverse drug events using multiple public health data sources. J Biomed Inform 2007; 40:382–389.
   PubMed Web of Science ®Google Scholar
• Wysowski DK. Surveillance of prescription drug-related mortality using death certificate data. Drug Saf 2007; 30:533–540.
   PubMed Web of Science ®Google Scholar
• Fredheim OM, Moksnes K, Borchgrevink PC, Kaasa S, Dale O. Clinical pharmacology of methadone for pain. Acta Anaesthesiol Scand 2008; 52:879–889.
   PubMed Web of Science ®Google Scholar
• Li Y, Kantelip JP, Gerritsen-van SP, Davani S. Interindividual variability of methadone response: impact of genetic polymorphism. Mol Diagn Ther 2008; 12:109–124.
   PubMed Web of Science ®Google Scholar
• Weschules DJ, Bain KT, Richeimer S. Actual and potential drug interactions associated with methadone. Pain Med 2008; 9: 315–344.
   PubMed Web of Science ®Google Scholar
• Andrews CM, Krantz MJ, Wedam EF, Marcuson MJ, Capacchione JF, Haigney MC. Methadone-induced mortality in the treatment of chronic pain: role of QT prolongation. Cardiol J 2009; 16:210–217.
   PubMed Web of Science ®Google Scholar
• Ehret GB, Desmeules JA, Broers B. Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology. Expert Opin Drug Saf 2007; 6:289–303.
   PubMed Web of Science ®Google Scholar
• Maremmani I, Pacini M, Cesaroni C, Lovrecic M, Perugi G, Tagliamonte A. QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur Addict Res 2005; 11:44–49.
   PubMed Web of Science ®Google Scholar
• Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf 2005; 14:747–753.
   PubMed Web of Science ®Google Scholar
• Methadone [package insert]. Roxane Laboratories, Inc. Columbus, OH.
   Google Scholar
• Bronstein AC, Spyker DA, Cantilena LR Jr., Green JL, Rumack BH, Giffin SL. 2008. Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 26th Annual Report. Clin Toxicol (Phila) 2009;47:911–1084.
   Web of Science ®Google Scholar
• Litovitz TL, Klein-Schwartz W, White S, Cobaugh DJ, Youniss J, Omslaer JC, . 2000. Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2001; 19:337–395.
   Web of Science ®Google Scholar
• Krantz MJ, Rowan SB, Schmittner J, Bucher BB. Physician awareness of the cardiac effects of methadone: results of a national survey. J Addict Dis 2007; 26:79–85.
   PubMed Web of Science ®Google Scholar
• Dershwitz, M. There should be a threshold dose for FDA black-box warning on droperidol. Anesth Analg. 2003; 97:1542–1543; author reply 1543.
   PubMed Web of Science ®Google Scholar